Extended Data Table 3 Additional Safety Measures from Randomization to Week 72

From: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

  1. Data are model based estimate (standard error) and were analyzed with log transformation, except for pulse rate data. MTD, maximum tolerated dose (10 or 15 mg).
Back to article page